We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$233M
Cap. Flow %
2.56%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMDX
126
Insight Molecular Diagnostics
IMDX
$144M
$10.2M 0.11%
142,800
+37,800
+36% +$3.47M
MAPS
127
DELISTED
WM TECHNOLOGY INC A
MAPS
$10.2M 0.11%
700,400
– –
KZR
128
DELISTED
Kezar Life Sciences
KZR
$9.94M 0.11%
115,000
+59,281
+106% +$3.92M
NVAX icon
129
Novavax
NVAX
$1.21B
$9.45M 0.1%
45,580
-154,715
-77% -$34.1M
CTMX icon
130
CytomX Therapeutics
CTMX
$694M
$9.27M 0.1%
1,821,868
+308,700
+20% +$1.65M
KALA icon
131
KALA BIO
KALA
$12.5M
$9.01M 0.1%
1,377
-811
-37% -$7M
NAUT icon
132
Nautilus Biotechnolgy
NAUT
$141M
$8.92M 0.1%
1,452,774
-93,926
-6% -$748K
PHGE icon
133
BiomX
PHGE
$1.98M
$8.61M 0.09%
14,808
+2,632
+22% +$2.04M
BMRN icon
134
BioMarin Pharmaceuticals
BMRN
$11.9B
$8.57M 0.09%
+110,900
New +$8.75M
CNVY
135
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
$8.4M 0.09%
1,000,000
– –
SYRS
136
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.21M 0.09%
183,750
– –
REGN icon
137
Regeneron Pharmaceuticals
REGN
$73B
$8.21M 0.09%
+13,560
New +$8.42M
NBP
138
NovaBridge Biosciences American Depositary Shares
NBP
$192M
$8.05M 0.09%
111,120
– –
EVH icon
139
CALL
Evolent Health
EVH
$380M
$7.75M 0.09%
+250,000
New +$6M
XENE icon
140
Xenon Pharmaceuticals
XENE
$6.18B
$7.29M 0.08%
477,000
-857,217
-64% -$14.9M
XFOR icon
141
X4 Pharmaceuticals
XFOR
$378M
$7.27M 0.08%
45,795
– –
NTLA icon
142
Intellia Therapeutics
NTLA
$1.52B
$7.14M 0.08%
+53,200
New +$8.05M
REUN
143
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$7M 0.08%
+307,694
New +$7.74M
SURF
144
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$6.89M 0.08%
+909,666
New +$5.82M
OWLT icon
145
Owlet
OWLT
$147M
$6.71M 0.07%
+85,714
New +$9.59M
SRPT icon
146
Sarepta Therapeutics
SRPT
$1.65B
$5.98M 0.07%
64,700
– –
RXDX
147
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$5.93M 0.07%
250,000
– –
NBTX
148
Nanobiotix
NBTX
$1.91B
$5.68M 0.06%
500,000
– –
APTO
149
DELISTED
Aptose Biosciences, Inc.
APTO
$5.66M 0.06%
5,765
-12,079
-68% -$15.1M
PRCT icon
150
Procept Biorobotics
PRCT
$1.02B
$5.15M 0.06%
+135,000
New +$5.18M
4 5
6
7 8

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.